Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.57 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | MAOB | P27338 | 1/20 | 0.48 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.47 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.47 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.46 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2773150 | 0.89 | FFAR4 (0.57) | FFAR4HPGDLMNAMAOBMTNR1A | |
| SCHEMBL14892610 | 0.88 | FFAR4 (0.59) | FFAR4HPGDLMNAMAOBMTNR1A | |
| Hydrochloric Acid SCHEMBL6289049 | 0.86 | FFAR4 (0.55) | FFAR4HPGDLMNANPC1RAB9A | |
| SCHEMBL3962253 | 0.86 | MAOB (0.61) | FFAR4HPGDLMNAMAOBNPC1 | |
| SCHEMBL11557673 | 0.84 | KDM4E (0.60) | FFAR4HPGDLMNAMAOBMTNR1A | |
| SCHEMBL7907439 | 0.84 | MAOB (0.56) | FFAR4MAOBNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL14891403 | 0.83 | FFAR4 (0.54) | FFAR4HPGDLMNAALDH1A1SMPD1 | |
| SCHEMBL21434703 | 0.83 | PTGER1 (0.57) | FFAR4HPGDLMNANPC1RAB9A | |
| SCHEMBL1958139 | 0.83 | FFAR4 (0.75) | FFAR4HPGDLMNANPC1MRGPRX4 | |
| SCHEMBL1318328 | 0.83 | FFAR4 (0.54) | FFAR4HPGDLMNAMAOBNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080274947-A1 | Hydroxy-Substituted Diphenylazetidinones for the Treatment of Hyperlipidemia | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-11-06 | — | — | US | disclosed |
| US-20080274947-A1 | Hydroxy-Substituted Diphenylazetidinones for the Treatment of Hyperlipidemia | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-11-06 | — | — | US | disclosed |
| EP-1954673-A1 | HYDROXY-SUBSTITUTED DIPHENYLAZETIDINONES FOR THE TREATMENT OF HYPERLIPIDAEMIA | Sanofi-Aventis Deutschland GmbH (DE) | 2008-08-13 | — | — | EP | disclosed |
| WO-2007059871-A1 | HYDROXY-SUBSTITUTED DIPHENYLAZETIDINONES FOR THE TREATMENT OF HYPERLIPIDAEMIA | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080274947-A1 | Hydroxy-Substituted Diphenylazetidinones for the Treatment of Hyperlipidemia | CYP46A1, GPR119, DHCR7 | FFAR4 251/4885HPGD 422/4885LMNA 2297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.